{"title":"Implications of the Choice of Different Calculation Concepts for eGFRcys-to-eGFRcre Ratio Among Community-Dwelling Older Adults","authors":"Xiufang Kong , Xue Li , Wei Wang","doi":"10.1016/j.ekir.2024.08.032","DOIUrl":"10.1016/j.ekir.2024.08.032","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Barbara Cellini , Michelle A. Baum , Yaacov Frishberg , Jaap W. Groothoff , Peter C. Harris , Sally A. Hulton , Felix Knauf , John Knight , John C. Lieske , W. Todd Lowther , Shabbir Moochhala , Lama Nazzal , Gregory E. Tasian , Jonathan M. Whittamore , David J. Sas
{"title":"Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory","authors":"Barbara Cellini , Michelle A. Baum , Yaacov Frishberg , Jaap W. Groothoff , Peter C. Harris , Sally A. Hulton , Felix Knauf , John Knight , John C. Lieske , W. Todd Lowther , Shabbir Moochhala , Lama Nazzal , Gregory E. Tasian , Jonathan M. Whittamore , David J. Sas","doi":"10.1016/j.ekir.2024.08.031","DOIUrl":"10.1016/j.ekir.2024.08.031","url":null,"abstract":"<div><div>Hyperoxaluria is a condition in which there is a pathologic abundance of oxalate in the urine through either hepatic overproduction (primary hyperoxaluria [PH]) or excessive enteric absorption of dietary oxalate (enteric hyperoxaluria [EH]). Severity can vary with the most severe forms causing kidney failure and extrarenal manifestations. To address the current challenges and innovations in hyperoxaluria, the 14th International Hyperoxaluria Workshop convened in Perugia, Italy, bringing together international experts for focused presentation and discussion. The objective of the following report was to disseminate an overview of the proceedings and provide substrate for further thought. The format of this paper follows the format of the meeting, addressing, “PH type 1” (PH1) first, followed by “surgery, genetics, and ethics in PH”, then “PH types 2 and 3,” (PH2 and PH3) and, finally, “EH.” Each session began with presentations of the current clinical challenges, followed by discussion of the latest advances in basic and translational research, and concluded with interactive discussions about prioritizing the future of research in the field to best serve the need of the patients.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142253223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
John P. Middleton , Shifeng Sun , Susan Murray , Clemontina A. Davenport , James P. Daubert
{"title":"Randomized Trial of Patiromer on Efficacy to Reduce Episodic Hyperkalemia in Patients with ESKD Treated With Hemodialysis","authors":"John P. Middleton , Shifeng Sun , Susan Murray , Clemontina A. Davenport , James P. Daubert","doi":"10.1016/j.ekir.2024.08.005","DOIUrl":"10.1016/j.ekir.2024.08.005","url":null,"abstract":"<div><h3>Introduction</h3><div>Individuals with end-stage kidney disease (ESKD) maintained on hemodialysis (HD) carry a high risk of cardiac arrhythmias. This risk is heightened by episodic hyperkalemia. The purpose of the study was to investigate whether patiromer administered daily reduced episodes of hyperkalemia in those with ESKD who receive HD, and to explore whether prescription of patiromer reduced the number of significant arrhythmia events.</div></div><div><h3>Methods</h3><div>This was a prospective, randomized, open-label trial. Eligible patients with ESKD on HD were identified. Participants were randomized 1:1 to patiromer versus usual care. Those randomized to patiromer were administered the medication daily, and the dose was titrated based on serum potassium concentrations at the start of weeks 1, 2, and 3. All participants received 7-day continuous cardiac monitors at baseline and at week 4.</div></div><div><h3>Results</h3><div>Of the 33 participants who were randomized, 1 withdrew due to adverse symptoms, and 1 withdrew due to pregnancy, leaving 31 in our analytic cohort. The mean age of randomized participants was 56 years, 55% were male, 81% were Black, and 10% were Hispanic/Latino. In week 4, the number of episodes of serum potassium ≥ 5.5 mEq/l was 13 in the patiromer group and 41 in the control group; with median number of episodes of hyperkalemia in the patiromer group significantly lower than that of control group (0 vs. 3, <em>P</em> = 0.024). In week 4 continuous cardiac monitors, 6 participants had > 1000/24 h premature ventricular contractions, 5 had no sustained ventricular tachycardia (VT), 3 had atrial fibrillation, and 1 had bradycardia, with no significant differences between the groups.</div></div><div><h3>Conclusion</h3><div>Patiromer administered daily reduced the frequency of hyperkalemia in study participants with ESKD who receive thrice-weekly HD. Larger studies are needed to determine whether patiromer reduces significant cardiac events.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jian Roushani , Abigail J. Berube , Matthew B. Lanktree
{"title":"Reporting of Race, Ethnicity, and Ancestry Remains Inadequate in Kidney Research","authors":"Jian Roushani , Abigail J. Berube , Matthew B. Lanktree","doi":"10.1016/j.ekir.2024.08.010","DOIUrl":"10.1016/j.ekir.2024.08.010","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142223892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chandana Guha , Rabia Khalid , Kylie-Ann Mallitt , Anita van Zwieten , Anna Francis , Siah Kim , Armando Teixeira-Pinto , Martha Aquino , Amelie Bernier-Jean , David W. Johnson , Deirdre Hahn , Donna Reidlinger , Elizabeth G. Ryan , Fiona Mackie , Hugh McCarthy , Julie Varghese , Charani Kiriwandeniya , Kirsten Howard , Nicholas Larkins , Luke Macauley , Steve McTaggart
{"title":"Perspectives of Caregivers on Access to Health Care for Children with CKD","authors":"Chandana Guha , Rabia Khalid , Kylie-Ann Mallitt , Anita van Zwieten , Anna Francis , Siah Kim , Armando Teixeira-Pinto , Martha Aquino , Amelie Bernier-Jean , David W. Johnson , Deirdre Hahn , Donna Reidlinger , Elizabeth G. Ryan , Fiona Mackie , Hugh McCarthy , Julie Varghese , Charani Kiriwandeniya , Kirsten Howard , Nicholas Larkins , Luke Macauley , Steve McTaggart","doi":"10.1016/j.ekir.2024.08.029","DOIUrl":"10.1016/j.ekir.2024.08.029","url":null,"abstract":"<div><h3>Introduction</h3><div>Inequitable access to health care based on demographic factors such as ethnicity, socioeconomic status and geographical location has been consistently found in children with chronic kidney disease (CKD). However, little is known about the perspectives of caregivers on accessing health care. We described caregivers’ perspectives on accessing health care for children with CKD from socioeconomically disadvantaged backgrounds and/or rural or remote areas.</div></div><div><h3>Methods</h3><div>Caregivers of Australian children aged 0 to 16 years, across all CKD stages, from low socioeconomic status backgrounds, and/or residing in rural or remote areas, purposively sampled from 5 centers, participated in semi structured interviews on accessing health care. Transcripts were analyzed thematically.</div></div><div><h3>Results</h3><div>From 32 interviews, we identified 6 themes: lack of agency undermining ability to seek care (obscurity of symptoms, uncertain and confused about care processes, and vulnerable and unable to advocate), losing trust in clinicians (confused by inconsistencies and ambiguities in advice, and distressed by lack of collaborative care), exasperated by organizational rigidity (frustrated by bureaucratic roadblocks, lack of access to specialist care in rural and remote settings, and inadequacies of support programs), compounding burden of caregiving (unsustainable financial pressure, debilitating exhaustion, and asymmetry of responsibility), intensifying strain on family (uprooting to relocate, sibling stress and neglect, and depending on family support), building resilience and stability (empowerment through education and confidence in technical and medical support).</div></div><div><h3>Conclusions</h3><div>Caregivers of children with CKD from disadvantaged backgrounds feel disempowered and vulnerable when accessing care for their child. Strategies are needed to improve access to health care for families who are socioeconomically or geographically disadvantaged.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sistiana Aiello , Sara Gastoldi , Elena Bresin , Miriam Galbusera , Caterina Mele , Erica Daina , Donata Santarsiero , Giorgia Comai , Gaetano La Manna , Carolina Martinatto , Ariela Benigni , Giuseppe Remuzzi , Marina Noris
{"title":"Exuberant Endothelial C5b-9 Formation in Recurrent and De Novo Posttransplant Thrombotic Microangiopathy","authors":"Sistiana Aiello , Sara Gastoldi , Elena Bresin , Miriam Galbusera , Caterina Mele , Erica Daina , Donata Santarsiero , Giorgia Comai , Gaetano La Manna , Carolina Martinatto , Ariela Benigni , Giuseppe Remuzzi , Marina Noris","doi":"10.1016/j.ekir.2024.08.014","DOIUrl":"10.1016/j.ekir.2024.08.014","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cong-Cong Liu , Jia-Ling Ji , Ze Wang , Xing-Jian Zhang , Lin Ding , Yao Zhang , Yan Zhou , Dong-Jie Zhang , Zhen-Lin Tang , Jing-Yuan Cao , Ai-Qing Zhang , Bi-Cheng Liu , Zuo-Lin Li , Rui-Xia Ma
{"title":"TRPC6-Calpain-1 Axis Promotes Tubulointerstitial Inflammation by Inhibiting Mitophagy in Diabetic Kidney Disease","authors":"Cong-Cong Liu , Jia-Ling Ji , Ze Wang , Xing-Jian Zhang , Lin Ding , Yao Zhang , Yan Zhou , Dong-Jie Zhang , Zhen-Lin Tang , Jing-Yuan Cao , Ai-Qing Zhang , Bi-Cheng Liu , Zuo-Lin Li , Rui-Xia Ma","doi":"10.1016/j.ekir.2024.08.019","DOIUrl":"10.1016/j.ekir.2024.08.019","url":null,"abstract":"<div><h3>Introduction</h3><div>Renal tubulointerstitial inflammation represents an effective indicator for predicting the progression of diabetic kidney disease (DKD). Mitophagy abnormality is 1 of the most important factors involved in tubule injury. However, the exact molecular mechanism underlying mitophagy abnormality-mediated tubulointerstitial inflammation in DKD remains poorly understood.</div></div><div><h3>Methods</h3><div>In this study, a streptozotocin-induced DKD mouse model was established and HK-2 cells treated with high glucose (HG) served as an <em>in vitro</em> model. Tubular mitophagy was regulated through pharmacological urolithin A (UA) administration. The functional effect of the transient receptor potential cation channel, subfamily C, member 6 (TRPC6) was explored using genetic interventions <em>in vivo</em> and <em>in vitro</em>.</div></div><div><h3>Results</h3><div>We found that renal tubulointerstitial inflammation in DKD was closely associated with mitophagy inhibition, which was mediated by disturbance of PINK1/Parkin pathway. Mitophagy activation significantly attenuated tubular injury and tubulointerstitial inflammation. Further, it was found that TRPC6 was markedly increased in DKD and played an essential role in mitophagy inhibition by activating calpain-1. Knockdown of <em>Trpc6</em> partially reversed mitophagy abnormality and consequently attenuated tubular injury and tubulointerstitial inflammation <em>in vivo</em> and <em>in vitro</em>. Finally, we found that tubular TRPC6-mediated mitophagy inhibition was blocked with BAPTA (a specific Ca<sup>2+</sup> chelator) or calpeptin (a specific calpain-1 inhibitor).</div></div><div><h3>Conclusion</h3><div>Our study reveals that TRPC6-calpain-1 axis promotes tubulointerstitial inflammation in DKD by inhibiting mitophagy.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elisabeth P. Lafaut , Pedro Fragoso , Mark Haas , Sanjeev Sethi
{"title":"De Novo Exostosin-Associated Membranous Nephropathy in Kidney Transplant","authors":"Elisabeth P. Lafaut , Pedro Fragoso , Mark Haas , Sanjeev Sethi","doi":"10.1016/j.ekir.2024.09.009","DOIUrl":"10.1016/j.ekir.2024.09.009","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ryan J. Bamforth , Thomas W. Ferguson , Navdeep Tangri , Claudio Rigatto , David Collister , Paul Komenda
{"title":"Cost-Utility of Real-Time Potassium Monitoring in United States Patients Receiving Hemodialysis","authors":"Ryan J. Bamforth , Thomas W. Ferguson , Navdeep Tangri , Claudio Rigatto , David Collister , Paul Komenda","doi":"10.1016/j.ekir.2024.08.007","DOIUrl":"10.1016/j.ekir.2024.08.007","url":null,"abstract":"<div><h3>Introduction</h3><div>Patients with kidney failure requiring hemodialysis are at high risk for hyperkalemia between treatments, which is associated with increased cardiovascular morbidity and mortality. Early detection of hyperkalemic events may be useful to prevent adverse outcomes and their associated costs. We performed a cost-utility analysis comparing an intervention where a real-time potassium monitoring device is administered in patients on hemodialysis in comparison to usual care.</div></div><div><h3>Methods</h3><div>We developed a cost-utility model with microsimulation from the perspective of the United States health care payer. Primary outcomes included the monthly cost-effectiveness threshold cost and break-even cost per patient attributable to the intervention and the incremental cost-effectiveness ratio comparing the intervention to usual care. A 25% reduction in hyperkalemic events was applied as a baseline device effectiveness estimate. Concurrent first and second order microsimulations were performed using 10%, 25%, and 50% effectiveness estimates as sensitivity analyses. Results are presented over a 10-year time horizon in 2022 United States dollars and a willingness-to-pay threshold of $100,000 per quality-adjusted life year (QALY) was considered.</div></div><div><h3>Results</h3><div>Over 10 years, threshold and break-even analysis yielded maximum monthly costs of $201.10 and $144.15 per patient, respectively. The intervention was associated with reduced mean costs ($6381.21) and increased mean QALYs (0.03) per patient; therefore, was considered dominant. In sensitivity analysis, the intervention was dominant in 99% of simulations performed at all effectiveness rates.</div></div><div><h3>Conclusion</h3><div>Implementing a real-time potassium monitoring device in patients on hemodialysis has the potential for cost savings and improved outcomes from the perspective of the United States health care payer.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yuanyuan Fang , Minjing Qin , Qitong Zheng , Kuilong Wang , Xin Han , Qiao Yang , Xia'nan Sang , Gang Cao
{"title":"Role of Bile Acid Receptors in the Development and Function of Diabetic Nephropathy","authors":"Yuanyuan Fang , Minjing Qin , Qitong Zheng , Kuilong Wang , Xin Han , Qiao Yang , Xia'nan Sang , Gang Cao","doi":"10.1016/j.ekir.2024.08.002","DOIUrl":"10.1016/j.ekir.2024.08.002","url":null,"abstract":"<div><div>Diabetic nephropathy (DN) is a prevalent microvascular complication that occurs often in individuals with diabetes. It significantly raises the mortality rate of affected patients. Therefore, there is an urgent need to identify therapeutic targets for controlling and preventing the occurrence and development of DN. Bile acids (BAs) are now recognized as intricate metabolic integrators and signaling molecules. The activation of BAs has great promise as a therapeutic approach for preventing DN, renal damage caused by obesity, and nephrosclerosis. The nuclear receptors (NRs), farnesoid X receptor (FXR), pregnane X receptor (PXR), vitamin D receptor (VDR); and the G protein-coupled BA receptor, Takeda G-protein-coupled receptor 5 (TGR5) have important functions in controlling lipid, glucose, and energy metabolism, inflammation, as well as drug metabolism and detoxification. Over the past 10 years, there has been advancement in comprehending the biology and processes of BA receptors in the kidney, as well as in the creation of targeted BA receptor agonists. In this review, we discuss the role of BA receptors, FXR, PXR, VDR, and TGR5 in DN and their role in renal physiology, as well as the development and application of agonists that activate BA receptors for the treatment of kidney diseases.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}